Abstract
Introduction: Enzyme replacement therapy in Pompe disease reduces short-term mortality. Contents: This therapy allows patients to maintain functional independence and adaptation of motor skills for patient participation in various aspects of daily life.
Conclusions: The approach with this patients should be multidisciplinary to provide comprehensive management of the clinical condition of each individual seeking treatment of the physical and emotional aspects that may be altered in the disease progression: musculoskeletal, cardiovascular, respiratory, swallowing, language, nutritional and psychological; also including palliative care and pain management.
References
Corrado B, Ciardi G, Iammarrone CS. Rehabilitation management of Pompe disease, from childhood trough adulthood: A systematic review of the literature. Neurol Int. 2019;11(2):7983. https://doi.org/10.4081/ni.2019.7983
Chien YH, Lee NC, Chen CA, Tsai FJ, Tsai WH, Shieh JY, et al. Long-term prognosis of patients with infantile-onset Pompe disease diagnosed by newborn screening and treated since birth. Jo Pediatr. 2015;166(4):985-91.e1-2:985-991.e2. https://doi.org/10.1016/j.jpeds.2014.10.068
Llerena Junior JC, Nascimento OJM, Oliveira ASB, Dourado Junior MET, Marrone CD, Siqueira HH, et al. Guidelines for the diagnosis, treatment and clinical monitoring of patients with juvenile and adult pompe disease. Arq Neuropsiquiatr. 2016;74(2):166-76. https://doi.org/10.1590/0004-282X20150194
Savegnago AK, da Silva RM, Jonhston C, Martins AM, de Melo APL, de Carvalho WB. Systematic review of function assessment scales in Pompe disease. Rev Paul Pediatr 2012;30(2):272-7. https://doi.org/10.1590/S0103-05822012000200018
Kishnani PS, Steiner RD, Bali D, Berger K, Byrne BJ, Case L, et al. Pompe disease diagnosis and management guideline. Genet Med. 2006;8(5):267-88. https://doi.org/10.1097/01.gim.0000218152.87434.f3
Barba Romero MÁ, Barrot Cortes E, Bautista Lorite J, Gutiérrez Rivas E, Illa Sendra I, Jiménez LM, et al. Guía clínica de la enfermedad de Pompe de inicio tardío. Rev Neurol. 2012;54:497. https://doi.org/10.33588/rn.5408.2012088
Klug TL, Swartz LB, Washburn J, Brannen C, Kiesling JL. Lessons learned from pompe disease newborn screening and follow-up. Int J Neonatal Screen. 2020;14;6(1):11. https://doi.org/10.3390/ijns6010011
van den Berg LEM. The musculoskeletal system in Pompe disease. Legatron Electronic Publishing; 2014. https://doi.org/http://hdl.handle.net/1765/51599.
Iolascon G, Vitacca M, Carraro E, Chisari C, Fiore P, Messina S, et al. The role of rehabilitation in the management of late-onset Pompe disease: a narrative review of the level of evidence. Acta Myol. 2018;37(4):241-51.
Mathews DJM, Alexander MAM. Pediatric rehabilitation, principles and practice. 5.a ed. Demos Medical Publishing; 2015.
Case LE, Kishnani PS. Physical therapy management of Pompe disease. Genet Med. 2006;8(5):318-27. https://doi.org/10.1097/01.gim.0000217789.14470.c5
Cupler EJ, Berger KI, Leshner RT, Wolfe GI, Han JJ, Barohn RJ, et al. Consensus treatment recommendations for late-onset Pompe disease. Muscle Nerve. 2012;45(3):319-33. https://doi.org/10.1002/mus.22329
Braddom RL. Physical medicine and rehabilitation. 4.a ed. Elsevier; 2011. https://doi.org/10.1016/B978-0-12-385157-4.00219-0
Iolascon G, Vitacca M, Carraro E, Chisari C, Fiore P, Messina S, et al. Adapted physical activity and therapeutic exercise in late-onset Pompe disease (LOPD): a two-step rehabilitative approach. Neurol Sci. 2020;41(4):859-68. https://doi.org/10.1007/s10072-019-04178-7
van den Berg LEM, Favejee MM, Wens SCA, Kruijshaar ME, Praet SFE, Reuser AJJ, et al. Safety and efficacy of exercise training in adults with Pompe disease: Evalution of endurance, muscle strength and core stability before and after a 12 week training program. Orphanet J Rare Dis. 2015;10 :87. https://doi.org/10.1186/s13023-015-0303-0
Vissing J. Exercise training in metabolic myopathies. Rev Neurol (Paris). 2016;172:559-65. https://doi.org/10.1016/j.neurol.2016.08.005
Tarnopolsky MA, Nilsson MI. Nutrition and exercise in Pompe disease. Ann Transl Med. 2019;7(13):282. https://doi.org/10.21037/atm.2019.05.52
Tucker-Bartley A, Lemme J, Gomez-Morad A, Shah N, Veliu M, Birklein F, et al. Pain Phenotypes in rare musculoskeletal and neuromuscular diseases. Neurosci Biobehav Rev. 2021;124:267-90. https://doi.org/10.1016/j.neubiorev.2021.02.009
de Visser M, Oliver DJ. Palliative care in neuromuscular diseases. Curr Opin Neurol. 2017;30(6):686-91. https://doi.org/10.1097/WCO.0000000000000493
Ortiz F, Rincón M, Mendoza JC. Texto de medicina física y rehabilitación, vol. 1. Manual Moderno; 2016.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.